Second quarter and first half year 2016 results

Oslo, 30 August 2016 – Please find enclosed the financial report and presentation for second quarter 2016.

Q2-16 PCIB Interim ReportingQ2-16 PCIB Presentation

Highlights

  • Granted Orphan Drug Designation of fimaporfin for treatment of bile duct cancer in EU

  • Commissioned independent expert evaluation of the early promising response data – results expected Q3 2016

  • Lancet Oncology publication of the fimaporfin (Amphinex) first-in-man phase I study – with independent expert commentary

  • fimaVacc ready for clinical validation – a major milestone towards potential commercialization

  • Initiated first research collaboration with commercial entity for fimaVacc

A presentation will be held today, Tuesday 30 August 2016, at Oslo Cancer Cluster Innovation Park.

Time: Tuesday August 30 2016, 09.00-10.00 hrs.

Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo.

Kind regards,Per WaldayCEO

Email: pw@pcibiotech.no
Mobile: +47 917 93 429

NewsKristin Eivindvik